GlassScriptPhysician profile
Shawn P Mcglaughlin
NPI 1114946563
$4,609.37
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $709 · 2021: $880 · 2022: $958 · 2023: $1,217 · 2024: $41.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $709.13 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $695.98 | 2019-2023 | Tradjenta, Stiolto Respimat, Synjardy |
| Astrazeneca Pharmaceuticals LP | $597.74 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $492.89 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $235.38 | 2021-2024 | |
| Astellas Pharma US INC | $214.51 | 2021-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $204.52 | 2019-2022 | |
| Lilly USA, LLC | $199.03 | 2019-2023 | Mounjaro |
| Pfizer INC. | $181.42 | 2019-2023 | |
| Silk Road Medical, INC. | $132.21 | 2022 | |
| Medtronic, INC. | $128.14 | 2023 | Intellis Adaptivestim |
| E.R. Squibb & Sons, L.L.C. | $111.76 | 2019-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $111.68 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $68.02 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.49 | 2019-2023 | Trintellix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $60.64 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.64 | 2022 | |
| Sanofi Pasteur INC. | $46.50 | 2021-2022 | |
| Dexcom, INC. | $44.93 | 2022-2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $33.45 | 2020-2021 | |
| Exact Sciences Corporation | $31.32 | 2023 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $29.05 | 2023 | Opsumit, Uptravi |
| Abbott Laboratories | $26.26 | 2021-2022 | |
| Axsome Therapeutics, INC. | $25.84 | 2023 | Auvelity |
| Corium, LLC | $19.76 | 2023 | Azstarys |
| Grifols USA, LLC | $17.57 | 2019 | |
| Urovant Sciences INC | $16.07 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.80 | 2022 | |
| Esperion Therapeutics, INC. | $15.10 | 2020 | |
| Allergan, INC. | $13.85 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Mcglaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.